Effect of Semaglutide on Subclinical Atherosclerosis and Cardiometabolic Compensation: A Real-World Study in Patients with Type 2 Diabetes

Background: Semaglutide is a recently approved glucagon-like peptide-1 receptor agonist. Several trials reported the protective effect of injectable semaglutide on cardiovascular (CV) risk by reducing major adverse cardiovascular events in type 2 diabetes patients. Strong preclinical evidence suppor...

Descripción completa

Detalles Bibliográficos
Autores principales: Patti, Angelo Maria, Giglio, Rosaria Vincenza, Allotta, Alberto, Bruno, Andreina, Di Bella, Tommaso, Pantea Stoian, Anca, Ciaccio, Marcello, Rizzo, Manfredi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10216597/
https://www.ncbi.nlm.nih.gov/pubmed/37239033
http://dx.doi.org/10.3390/biomedicines11051362

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10216597/
https://www.ncbi.nlm.nih.gov/pubmed/37239033
http://dx.doi.org/10.3390/biomedicines11051362

Ejemplares similares